Prediabetic State
Recent clinical, regulatory, research and industry developments relating to this disease.
Impact of dietary interventions on pre-diabetic oral and gut microbiome, metabolites and cytokines.
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
From Pre-Diabetes to Diabetes: Diagnosis, Treatments and Translational Research.
The Integrative Human Microbiome Project.
Human gut microbiota changes reveal the progression of glucose intolerance.
Standards of medical care in diabetes--2011.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 3 clinical trials expected to report results, the earliest in Q3 2028.
Clinical MilestonesViewHide
- 2026-07-10Clinical and Nutrigenetic Assessment of Zinc in Participants With PrediabetesResults expected Q3 2028
- 2026-07-06Human Models of Selective Insulin Resistance: Diazoxide, Part IResults expected Q3 2029
- 2025-12-17CSP #2002 - Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes (VA-IMPACT)Results expected Q3 2029
- 2026-05-01Use of Empagliflozin to Treat Prediabetes - a Randomized, Double-blind, Placebo-controlled 13-week Intervention TrialPrimary completion
- 2026-03-31A Randomized Controlled Study on the Effects of Xuezhikang and Atorvastatin on Blood Glucose and Lipid Levels in Patients With Dyslipidemia and PrediabetesPrimary completion
- 2026-07-10ClinicalClinical and Nutrigenetic Assessment of Zinc in Participants With PrediabetesResults expected Q3 2028
- 2026-07-06ClinicalHuman Models of Selective Insulin Resistance: Diazoxide, Part IResults expected Q3 2029
- 2026-05-01ClinicalUse of Empagliflozin to Treat Prediabetes - a Randomized, Double-blind, Placebo-controlled 13-week Intervention TrialPrimary completion
- 2026-03-31ClinicalA Randomized Controlled Study on the Effects of Xuezhikang and Atorvastatin on Blood Glucose and Lipid Levels in Patients With Dyslipidemia and PrediabetesPrimary completion
- 2025-12-17ClinicalCSP #2002 - Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes (VA-IMPACT)Results expected Q3 2029
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Prediabetic State3
- Microbiota2
- Cardiology1
- Cardiovascular Diseases1
- Diabetes Mellitus1
- Gastrointestinal Microbiome1
- Hyperglycemia1
- Infant, Premature1
Leading journals6
- European heart journal2
- BMJ (Clinical research ed.)1
- Cardiovascular diabetology1
- Diabetes1
- Diabetes care1
- International journal of obesity (2005)1
Leading researchers8
- Ceriello A2
- Cosentino F2
- Grant PJ2
- Marx N2
- Sattar N2
- Valensi P2
- Yang Y2
- Aboyans V1
Affiliations (unnormalised)6
- Affiliated Hospital of Guangdong Medical University1
- George Institute for Global Health1
- Goldschleger School of Dental Medicine1
- Institute of Life Course and Medical Sciences1
- Karolinska Institutet1
- Key Laboratory of Neuroscience1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Prediabetic state is the period before symptomatic diabetes develops. It is described as a preceding condition of diabetes and is associated with glucose abnormalities that may be detected before overt disease appears.
The supplied grounding does not identify a specific cause or aetiology for prediabetic state. It only indicates that certain risk factors can be observed in people who later develop insulin resistance and type 2 diabetes.
The grounding links prediabetic state to insulin resistance and to glucose-related abnormalities that precede symptomatic diabetes. It also highlights interest in host-microbiome interactions, including microbiota, diet, and the gastrointestinal microbiome, as possible contributors to the biological changes seen in this period.
The grounding does not provide a defined list of risk factors. It does state that certain risk factors can be observed in subjects who subsequently develop insulin resistance and type 2 diabetes.
Diagnosis is based on glucose criteria, with fasting plasma glucose testing and oral glucose tolerance testing described as common modalities. The literature grounding also mentions therapy and translational research, but it does not specify a standard treatment class for prediabetic state.
AI-generated summary grounded in MeSH and 3 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
The time period before the development of symptomatic diabetes. For example, certain risk factors can be observed in subjects who subsequently develop INSULIN RESISTANCE as in type 2 diabetes (DIABETES MELLITUS, TYPE 2).
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.